sar425899 sanofi dual agonist glp-1 glucagon Transforming obesity: The advancement of multi-receptor drugs: Cell How glucagon-like peptide 1 receptor

Ozempic and other GLP-1 receptor agonists can increase insulin secretion, suppress glucagon release, slow digestion, and more

It has been studied in human clinical trials and shown to support metabolic balance, healthy blood glucose regulation, inflammation management, and improved insulin function

Here's what researchers found.

Gastric inhibitory polypeptide (GIP) and glucagonlike peptide1 (GLP1) are the two primary incretin hormones secreted from the intestine on ingestion of glucose or nutrients to stimulate insulin secretion from pancreatic cells

However, the molecular details of ago-allosterism remain elusive

There was an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, nephrolithiasis, interstitial nephritis and drug-induced pancreatitis.